{
  "extraction_metadata": {
    "timestamp": "2025-09-05T09:35:45.865595",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 6,
    "total_picos": 10
  },
  "picos_by_country": {
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival, progression-free survival, health-related quality of life, objective response rate (37.1% [95% CI 28.6 to 46.2], measured by RECIST 1.1 criteria), adverse effects"
        },
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": "overall survival, progression-free survival, health-related quality of life, objective response rate (37.1% [95% CI 28.6 to 46.2], measured by RECIST 1.1 criteria), adverse effects"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 4891
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation and failure of at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sotorasib",
          "Outcomes": "treatment with sotorasib (currently approved as of 02/22) following failure of at least one systemic therapy; recommendation based on Level 1b evidence and stronger consensus"
        }
      ],
      "ChunksUsed": 4,
      "ContextTokens": 692
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "objective response rate (ORR), median progression-free survival (mPFS), Grade 3 or higher adverse events (including diarrhoea, ALT increase, AST increase, neutropenia, fatigue, febrile neutropenia) as reported in the CodeBreaK 200 Phase 3 study, no difference in ORR and mPFS between patients with KRAS mutation and KRAS wild type in retrospective inventories (IMMUNOTARGET [2b], Keynote 042 [1b])"
        },
        {
          "Population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "objective response rate (ORR), median progression-free survival (mPFS), Grade 3 or higher adverse events (including diarrhoea, ALT increase, AST increase, neutropenia, fatigue, febrile neutropenia) as reported in the CodeBreaK 200 Phase 3 study, no difference in ORR and mPFS between patients with KRAS mutation and KRAS wild type in retrospective inventories (IMMUNOTARGET [2b], Keynote 042 [1b])"
        }
      ],
      "ChunksUsed": 16,
      "ContextTokens": 3464
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        },
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        }
      ],
      "ChunksUsed": 9,
      "ContextTokens": 1934
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "symptom control, preservation of quality of life, prolonged survival"
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1539
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "potential risk of serious side effects on the skin"
        },
        {
          "Population": "Advanced or metastatic non-small cell bronchial cancer: in the presence of a KRAS p.G12C mutation, having escaped a second line of treatment",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "potential risk of serious side effects on the skin"
        }
      ],
      "ChunksUsed": 14,
      "ContextTokens": 3364
    }
  }
}